Home
/
REGENXBIO Inc.
/
Financials
/
Quarterly
REGENXBIO Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that REGENXBIO Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q1
2018
Mar 31, 2018
$132.39M
May 8, 2018
Q3
2017
Sep 30, 2017
$1.34M
Nov 8, 2017
Q2
2017
Jun 30, 2017
$6.56M
Aug 8, 2017
Q1
2018
Mar 31, 2017
$455.0K
May 8, 2018
Q3
2017
Sep 30, 2016
$125.0K
Nov 8, 2017
Q2
2017
Jun 30, 2016
$2.38M
Aug 8, 2017
Q1
2017
Mar 31, 2016
$393.0K
May 9, 2017
Q3
2016
Sep 30, 2015
$1.14M
Nov 9, 2016
Q2
2016
Jun 30, 2015
$1.36M
Aug 9, 2016
Q1
2016
Mar 31, 2015
$644.0K
May 5, 2016
Q3
2015
Sep 30, 2014
$483.0K
Nov 5, 2015
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$29.73M
Nov 6, 2025
Q2
2025
Jun 30, 2025
$21.36M
Aug 7, 2025
Q1
2025
Mar 31, 2025
$89.01M
May 12, 2025
Q3
2025
Sep 30, 2024
$24.20M
Nov 6, 2025
Q2
2025
Jun 30, 2024
$22.30M
Aug 7, 2025
Q1
2025
Mar 31, 2024
$15.62M
May 12, 2025
Q3
2024
Sep 30, 2023
$28.91M
Nov 6, 2024
Q2
2024
Jun 30, 2023
$19.98M
Aug 1, 2024
Q1
2024
Mar 31, 2023
$19.14M
May 8, 2024
Q3
2023
Sep 30, 2022
$26.51M
Nov 8, 2023
Q2
2023
Jun 30, 2022
$32.65M
Aug 2, 2023
Q1
2023
Mar 31, 2022
$22.22M
May 3, 2023
Q3
2022
Sep 30, 2021
$30.77M
Nov 3, 2022
Q2
2022
Jun 30, 2021
$22.04M
Aug 3, 2022
Q1
2022
Mar 31, 2021
$18.88M
May 4, 2022
Q3
2021
Sep 30, 2020
$98.91M
Nov 2, 2021
Q2
2021
Jun 30, 2020
$16.57M
Aug 9, 2021
Q1
2021
Mar 31, 2020
$17.64M
May 5, 2021
Q3
2020
Sep 30, 2019
$14.70M
Nov 4, 2020
Q2
2020
Jun 30, 2019
$7.88M
Aug 6, 2020
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($61.94M)
Nov 6, 2025
Q2
2025
Jun 30, 2025
($70.87M)
Aug 7, 2025
Q1
2025
Mar 31, 2025
$6.08M
May 12, 2025
Q3
2025
Sep 30, 2024
($59.60M)
Nov 6, 2025
Q2
2025
Jun 30, 2024
($52.99M)
Aug 7, 2025
Q1
2025
Mar 31, 2024
($63.33M)
May 12, 2025
Q3
2024
Sep 30, 2023
($61.87M)
Nov 6, 2024
Q2
2024
Jun 30, 2023
($72.06M)
Aug 1, 2024
Q1
2024
Mar 31, 2023
($66.68M)
May 8, 2024
Q3
2023
Sep 30, 2022
($75.48M)
Nov 8, 2023
Q2
2023
Jun 30, 2022
($68.18M)
Aug 2, 2023
Q1
2023
Mar 31, 2022
($76.72M)
May 3, 2023
Q3
2022
Sep 30, 2021
($58.41M)
Nov 3, 2022
Q2
2022
Jun 30, 2021
($57.64M)
Aug 3, 2022
Q1
2022
Mar 31, 2021
($50.14M)
May 4, 2022
Q3
2021
Sep 30, 2020
$8.79M
Nov 2, 2021
Q2
2021
Jun 30, 2020
($33.76M)
Aug 9, 2021
Q1
2021
Mar 31, 2020
($40.04M)
May 5, 2021
Q3
2020
Sep 30, 2019
($34.58M)
Nov 4, 2020
Q2
2020
Jun 30, 2019
($1.46M)
Aug 6, 2020
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($52.41M)
Nov 6, 2025
Q2
2025
Jun 30, 2025
($63.28M)
Aug 7, 2025
Q1
2025
Mar 31, 2025
$12.13M
May 12, 2025
Q3
2025
Sep 30, 2024
($62.08M)
Nov 6, 2025
Q2
2025
Jun 30, 2024
($56.04M)
Aug 7, 2025
Q1
2025
Mar 31, 2024
($63.86M)
May 12, 2025
Q3
2024
Sep 30, 2023
($64.96M)
Nov 6, 2024
Q2
2024
Jun 30, 2023
($73.11M)
Aug 1, 2024
Q1
2024
Mar 31, 2023
($66.16M)
May 8, 2024
Q3
2023
Sep 30, 2022
($71.05M)
Nov 8, 2023
Q2
2023
Jun 30, 2022
($62.53M)
Aug 2, 2023
Q1
2023
Mar 31, 2022
($71.53M)
May 3, 2023
Q3
2022
Sep 30, 2021
($57.35M)
Nov 3, 2022
Q2
2022
Jun 30, 2021
($52.23M)
Aug 3, 2022
Q1
2022
Mar 31, 2021
($44.04M)
May 4, 2022
Q3
2021
Sep 30, 2020
$13.95M
Nov 2, 2021
Q2
2021
Jun 30, 2020
($41.83M)
Aug 9, 2021
Q1
2021
Mar 31, 2020
($37.70M)
May 5, 2021
Q3
2020
Sep 30, 2019
($35.90M)
Nov 4, 2020
Q2
2020
Jun 30, 2019
($36.87M)
Aug 6, 2020